Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Predicting Heart Problems After Liver Transplant

By HospiMedica staff writers
Posted on 21 Mar 2006
A study comparing the scores of three global cardiovascular disease risk-stratification algorithms in liver transplant patients found that two of the methods were better than the third.

Researchers at Virchow-Klinikum (Berlin, Germany) retrospectively studied 303 patients who had received a liver transplant between 1988 and 1994. They gathered clinical and demographic data at six months post-transplant and used it to calculate three established cardiovascular risk scores: the Framingham risk score (FRS), the German prospective cardiovascular Münster study (PROCAM), and the European systematic coronary risk evaluation project (SCORE), all of which predict the 10-year-risk of coronary or cardiovascular events or fatalities.

The researchers, led by Dr. Olaf Guckelberger of the department of general, visceral, and
transplantation surgery at the clinic, then compared the actual incidence of cardiovascular events, such as myocardial infarction (MI) and coronary heart disease over 10 years post-transplant to better understand the predictive power of each score. They found that PROCAM and SCORE provided excellent measures to discriminate between patients at high or low risk for coronary events, but that the Framingham risk score did not identify high-risk liver transplant recipients as accurately. The findings were published in the March 2006 issue of Liver Transplantation.

Patients who receive liver transplants often have an increased prevalence of cardiovascular risk factors, and cardiovascular events are a major source of their morbidity and mortality. Due to excellent long-term survival, there is an increasing emphasis on identifying transplant recipients at risk for immunosuppression-related late complications.



Related Links:
Virchow-Klinikum
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Mobile Cart
MS550
New
Multi-Parameter Patient Monitor
S90
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.